Logo

Jooish

HomeSitesGroupsStatusPodcasts
Sign InSign Up
JBizNews

Ascentage Says China to Add Leukemia Drug Lisaftoclax to National Insurance List

Nov 15, 2026·3 min read

Blood-sample tubes in an illustrative archive photograph, not an Ascentage product or patient sample. Photo: Kaboompics / Pexels, Pexels License. Cropped and resized.

Ascentage Pharma says its leukemia drug lisaftoclax will enter China’s national drug reimbursement list for the first time, giving the company a new route to reach eligible patients through the country’s insurance system.

The company announced the coverage Sunday, November 15, following the Chinese government’s publication of the updated list on November 14. The changes take effect January 1, 2027. This is an insurance-coverage decision, not a new drug approval.

The company’s announcement also says its other marketed cancer drug, olverembatinib, renewed its place on the list through renegotiation. Ascentage says all approved indications for its two drugs are now covered.

Which patients are covered

Lisaftoclax’s coverage is for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, known as CLL/SLL, who have already received at least one systemic treatment that included a BTK inhibitor, a type of targeted cancer medicine.

Ascentage said olverembatinib’s renewed coverage includes adults with chronic-phase chronic myeloid leukemia who are resistant or intolerant to first- and second-generation tyrosine kinase inhibitors. It also includes adults with chronic-phase or accelerated-phase disease carrying the T315I mutation.

The drugs are taken by mouth. Lisaftoclax was approved in China in July 2025 and olverembatinib in November 2021, according to the company. Neither has been approved by the U.S. Food and Drug Administration.

Coverage is not the same as free treatment

Getting onto the list matters because it allows eligible use to be reimbursed under China’s insurance rules. It does not mean every patient receives the medicine without paying.

The National Healthcare Security Administration’s notice says local authorities set how costs are divided between the insurance fund and the insured person. Payment also depends on the diagnosis, the drug’s approved use and the list’s coverage limits.

Ascentage did not disclose the negotiated prices or estimate how much individual patients would save. Its expectation that coverage will improve access is a company forecast, not a measured result of the new policy, which has not yet taken effect.

A commercial step, with results still ahead

For Ascentage, the change expands the insurance-backed market for lisaftoclax while preserving coverage for olverembatinib. The company jointly commercializes olverembatinib in China with Innovent Biologics.

Actual sales and patient access will depend on the terms of coverage and how the medicines become available through hospitals and pharmacies. The national notice calls for provinces to prepare the updated systems and drug listings before implementation.

The announcement does not report new clinical-trial results, change either drug’s U.S. regulatory status or establish a specific benefit for patients outside the covered groups.

JBizNews Desk | New York

© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.

View original on JBizNews
HomeSitesGroupsStatusPodcastsSign In